Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study
1. Scholar Rock's trial shows enhanced lean mass preservation with apitegromab. 2. Tirzepatide, used in LLY's drugs, leads to significant lean mass loss. 3. Combining apitegromab with tirzepatide reduces lean mass loss by half. 4. Juvena Therapeutics collaborates with LLY on muscle health and body composition. 5. LLY's Zepbound maintains flat pricing for consumer accessibility.